GLP-1 Drugs and Older Adults: What Seniors Should Know Before Starting Ozempic or Wegovy

Most of the coverage of GLP-1 drugs has focused on younger adults - the before-and-after photos, the celebrity endorsements, the insurance coverage fights. What has gotten almost no attention is how the picture changes for people over 65.

That matters right now because Medicare coverage for GLP-1 drugs expanded significantly in 2025 and 2026, putting them within reach for millions of older adults for the first time. Prescriptions are climbing among people in their 70s and 80s. And the risks specific to that age group are not getting nearly enough discussion.

What GLP-1 drugs actually do

GLP-1 agonists - semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and others - mimic a hormone your gut releases after eating. They slow digestion, reduce appetite, and signal the brain to stop eating sooner. The result is significant weight loss, typically 10-20% of body weight over a year of use.

They also have meaningful cardiovascular benefits that are largely independent of weight loss. The SELECT trial, published in 2023, showed semaglutide reduced major cardiac events by about 20% in people who were overweight but did not have diabetes. That finding is relevant for older adults, who carry the highest cardiovascular risk of any age group.

So these are genuinely useful drugs. The question is not whether they work. It's whether the full risk picture has been worked out for people over 65 - and the honest answer is: not really.

The muscle loss problem

When people lose weight on GLP-1 drugs, they lose fat, but they also lose muscle. A 2026 meta-analysis of 20 randomized trials found that lean mass made up 25% to 39% of the total weight lost on incretin drugs, around 35% with semaglutide and around 25% with tirzepatide. In younger adults with excess weight, losing some muscle alongside fat is manageable. In older adults, it's a more serious concern.

Sarcopenia, the age-related loss of muscle mass and strength, is already common by 60: pooled prevalence estimates for adults 60 and older run from about 10% to 27%, depending on which diagnostic definition a study uses. It's a major driver of falls, fractures, functional decline, and loss of independence. GLP-1 drugs don't cause sarcopenia, but they can accelerate it if muscle mass isn't actively preserved during weight loss.

The clinical trials that established GLP-1 safety and efficacy enrolled relatively few participants over 75. The STEP trials for semaglutide and SURMOUNT trials for tirzepatide included older adults, but not in numbers large enough to give a clear picture of how body composition changes differ by age. What we know about GLP-1s and muscle loss in the 70-and-over population is largely extrapolated from smaller studies and clinical observation.

Any older adult starting a GLP-1 drug should have a plan to preserve muscle, not just a prescription. That means adequate protein intake (the PROT-AGE expert group recommends at least 1.0 to 1.2 grams per kilogram of body weight daily for healthy older adults, and 1.2 to 1.5 grams for those with acute or chronic illness), resistance exercise at least twice a week, and monitoring of strength and function, not just the scale.

Bone density is the second concern

Weight loss - from any cause - is associated with some reduction in bone mineral density. Bone responds to mechanical load; as body weight drops, so does the stress on the skeleton, which can reduce bone density over time. For older adults, who already face elevated fracture risk from osteoporosis, this is not a minor consideration.

The data on GLP-1 drugs and bone density specifically is still thin. Some studies suggest the cardiovascular and anti-inflammatory effects of GLP-1 drugs may be partially protective for bone, but the weight-loss effect likely dominates for most people. Older adults who already have osteopenia or osteoporosis should discuss this specifically with their doctor before starting.

A baseline DEXA scan before starting a GLP-1 drug - and a follow-up after 12 months - is reasonable. If your parent's doctor hasn't mentioned it, bring it up.

What Medicare covers in 2026

The coverage picture has changed substantially. Medicare has covered GLP-1 drugs for diabetes management for years (primarily Ozempic and similar formulations prescribed for blood sugar control). What changed in 2024 and 2025 is coverage for cardiovascular risk reduction in non-diabetic patients, based on the SELECT trial data.

Medicare Part D does not cover drugs used only for weight loss, but it can cover a drug when it is prescribed for a separate medically accepted indication. In March 2024 the FDA approved semaglutide (sold as Wegovy) to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who also have obesity or overweight, and that indication is the route by which some Part D plans cover it. Whether your own plan does is a formulary question, so check before you assume.

The out-of-pocket cost still varies significantly. Part D now caps what an enrollee pays out of pocket for covered drugs each year: the cap started at $2,000 in 2025 and is $2,100 for 2026. That cap only helps if your specific plan covers the drug, so check your plan's formulary before assuming coverage.

When GLP-1 drugs make sense for older adults

Weight loss in older adults is not always beneficial. Unintentional weight loss is actually a marker for poor health outcomes in this age group, and some studies suggest that older adults with mild to moderate overweight have lower mortality than those at a 'normal' BMI - a pattern sometimes called the obesity paradox.

That doesn't mean GLP-1 drugs are wrong for older adults. There are situations where the benefits are clear: significant obesity that limits mobility or function, obesity combined with cardiovascular disease, type 2 diabetes with poor blood sugar control, or obesity that is causing joint pain severe enough to affect quality of life.

The situation where it's less clear-cut: an older adult who is modestly overweight, has no major metabolic or cardiovascular complications, and is otherwise functional. In that case, the cardiovascular benefits may be real, but the risk of accelerated muscle loss warrants a careful conversation rather than a straightforward prescription.

Questions to ask the doctor

If you or a parent is considering a GLP-1 drug, these are worth raising before starting:

Do I have a current DEXA scan on file? If not, can we get a baseline before starting? What is my current muscle mass and bone density?

What is the plan to preserve muscle during weight loss? Is there a specific protein target and an exercise recommendation?

Are we starting at a lower dose than standard protocols, given my age? Older adults often tolerate a slower dose increase better, with less nausea and fatigue.

How will we track whether this is working well over 6-12 months? What would make us reconsider?

Does my Medicare plan cover this, and what's the prior authorization process?

Where this leaves families

GLP-1 drugs are real medicine with real benefits. For the right older adult, they can reduce cardiovascular risk, improve blood sugar control, and restore mobility that obesity has limited. None of that is in dispute.

What is worth knowing: the safety data for people over 75 is thin, the muscle loss risk is more consequential in older bodies than younger ones, and the bone density effect warrants monitoring that most prescribers aren't routinely ordering. That doesn't make these drugs off-limits. It makes the conversation with a doctor more important than just asking "is this covered."

Sources

Primary sources for the figures and guidance on this page:

Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine, 2023 (PubMed) - The SELECT trial cited in this article: in adults with preexisting cardiovascular disease and overweight or obesity but without diabetes, semaglutide reduced major cardiovascular events versus placebo (hazard ratio 0.80, about a 20% relative reduction).

Vergara-Alvira MS, et al. Effects of GLP-1 receptor agonists on lean mass in patients with obesity: systematic review and meta-analysis. International Journal of Obesity, 2026 (PubMed) - Supports this article's core muscle-loss concern: GLP-1 receptor agonist treatment produced significant absolute lean-mass loss (semaglutide about -5.4 kg), and the authors recommend pairing treatment with nutrition and resistance exercise to preserve muscle.

Winter JE, et al. BMI and all-cause mortality in older adults: a meta-analysis. American Journal of Clinical Nutrition, 2014 (PubMed) - Meta-analysis of 32 studies finding that being overweight was not associated with increased mortality risk in older adults, the pattern this article describes as the obesity paradox.